| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2009-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2011-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011511002-A |
| titleOfInvention |
Intralymphatic chemotherapy drug carrier |
| abstract |
A chemotherapeutic composition for subcutaneous administration can be constructed that is due to preferential lymphatic accumulation but also provides a therapeutic systemic concentration that is not toxic. The composition may comprise a pharmaceutically acceptable carrier and a nanoconjugate configured for preferential lymphatic accumulation after subcutaneous administration. The nanoconjugate may comprise a nanocarrier configured for preferential lymphatic accumulation after subcutaneous or intrastitial administration and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate may have a dimension of about 10 to about 50 nm. The nanoconjugate may also be loaded with about 10 to about 50% w / w chemotherapeutic agent. The nanocarrier may be a hyaluronic acid polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier may be a dendrimer. [Selection] Figure 1 (A) |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022508458-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7199794-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016216454-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7235870-B2 |
| priorityDate |
2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |